Navigation Links
Results of the Phase III Pivotal Study of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults Presented at National Scientific Meeting of Psychiatrists
Date:5/8/2008

VYVANSE demonstrated significant improvement in ADHD symptoms in adults

WASHINGTON, May 8 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today presented the results of a phase III pivotal study in which VYVANSE demonstrated significant improvements in Attention Deficit Hyperactivity Disorder (ADHD) symptoms in adults and met all safety and efficacy endpoints.

"Adults with ADHD often find it challenging to focus and organize during the day. The disorder may impact many aspects of their lives from career to family and personal commitments," said Lenard A. Adler, M.D., lead researcher in this study and director of the Adult ADHD program at the NYU Langone Medical Center, associate professor of psychiatry, neurology and child and adolescent psychiatry at the New York University School of Medicine, as well as author of Scattered Minds: Help and Hope for Adults with ADHD (G. P. Putnam's Sons 2006). "This study demonstrated that VYVANSE significantly improved ADHD symptoms in adults, including inattention, such as the ability to focus, organize and complete tasks, which are essential during an adult day, as well as hyperactivity, such as restlessness, and impulsivity."

This double-blind, placebo-controlled, four-week, forced-dose study in 414 adults aged 18 to 55 years showed that treatment with VYVANSE at all doses studied (30 mg, 50 mg, 70 mg) provided a significant reduction in ADHD Rating Scale (ADHD-RS-IV) scores within one week that were observed throughout the full treatment period. At endpoint, VYVANSE demonstrated a significant improvement in ADHD symptoms, based on a 43 percent reduction in ADHD-RS scores. This is the largest placebo-controlled stimulant trial of ADHD in adults conducted to date.

Additional Study Findings

Investigators also measured the efficacy of VYVANSE with the Clinical Global Impressions-Improvement (CGI-I) scale and found that the percent
'/>"/>

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
3. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
4. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
5. Tapestry Reports Second Quarter 2007 Results
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
8. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
9. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
10. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 2014  Aethlon Medical, Inc. (OTCQB:AEMD), announced today that ... approximately $3.3 million at a price of $0.30 per ... focused investor. Each unit consists of one common share ... warrant. Each whole warrant entitles the holder to acquire ... a period of five years from closing.  ...
(Date:11/26/2014)... Texas , Nov. 26, 2014 ... today announced the completion of previously announced concurrent ... million.  After fees and estimated offering expenses, Lexicon ... the transactions.  The transactions consisted of: ... common stock, pursuant to a registration statement that ...
(Date:11/26/2014)... -- Investor-Edge has initiated coverage on the following ... PLC (NASDAQ: HZNP ), Endocyte Inc. (NASDAQ: ... ), and Theravance Inc. (NASDAQ: THRX ). Free ... http://investor-edge.com/register . On Tuesday, November 25, 2014, the ... Industrial Average edged 0.02% lower, to finish the day at ...
Breaking Medicine Technology:Aethlon Medical Announces $3.3 Million Equity Investment 2Aethlon Medical Announces $3.3 Million Equity Investment 3Lexicon Announces Completion Of $280 Million In Financing Transactions 2Lexicon Announces Completion Of $280 Million In Financing Transactions 3Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 2Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 3Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 4Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 5
(Date:11/28/2014)... Written and narrated by award winning author Dr. James ... Happiest Man In the World: Life Lessons From a Cultural ... Project C.U.R.E. came to be. , Raised in the Boise ... Richard W. Jackson, Dr. Jackson exceeded his goal of being ... he wasn’t happy. Prompted by this realization, James and his ...
(Date:11/28/2014)... (PRWEB) November 28, 2014 Not only ... create products free of petroleum, parabens and other cancer-causing ... that fund research, education and awareness programs that help ... staff and owners have raised an incredible, record-breaking contribution ... the Cure, sales of the Sweet Red Rose Whip ...
(Date:11/28/2014)... Mabel’s Labels , the market ... an award-winning company established by four moms, today announced ... Tricia Mumby have been honored with a 2014 RBC ... PROFIT Award for Excellence in Entrepreneurship. , All 4 ... Mumby) accepted the award on behalf of Mabel’s Labels ...
(Date:11/28/2014)... Miami, FL (PRWEB) November 28, 2014 Lice ... service areas of its in-home head lice service for ... location in the center of Coral Gables on Pone De-leon ... in Bay Harbor Islands that service Miami-Dade & Broward. ... physical salon in South Florida which has been treating families ...
(Date:11/28/2014)... 2014 Schools like Centra Rivermont ... quality commercial playground equipment to its students. That ... supply an affordable play structure at its mental ... Centra provides comprehensive programs for children who are ... services. They have served the needs of ...
Breaking Medicine News(10 mins):Health News:Thanksgiving Weekend Audiobook Treat! “The Happiest Man In the World: Life Lessons From a Cultural Economist” by Dr. James W. Jackson 2Health News:Éminence Organic Skin Care Donates Record-breaking $30,000 to Breast Cancer Research 2Health News:Éminence Organic Skin Care Donates Record-breaking $30,000 to Breast Cancer Research 3Health News:Mabel's Labels’ Co-Founders Named A Winner In The 2014 RBC Canadian Women Entrepreneur Awards Program; A Second-Time Win For The Brand 2Health News:Mabel's Labels’ Co-Founders Named A Winner In The 2014 RBC Canadian Women Entrepreneur Awards Program; A Second-Time Win For The Brand 3Health News:Lice Troopers Lice Removal Service Expands in Miami-Dade 2Health News:Centra Rivermont (VA) Provides School Playground Equipment from APCPLAY© for Special Needs Students 2Health News:Centra Rivermont (VA) Provides School Playground Equipment from APCPLAY© for Special Needs Students 3
... University and Harvard University have collaboratively developed a new theoretical ... sequences, even though there are many obstacles in the way ... in the scientific journal Nature Physics . , In ... so that different cells carry out the right tasks at ...
... important tasks of the immune system is to identify what ... then the body,s own structures will be attacked, the result ... mellitus type 1 or multiple sclerosis. The only way to ... that turn against the body,s own tissue in other ...
... Gen-Probe Incorporated (Nasdaq: GPRO ) announced that shareholders ... of Tepnel by Gen-Probe by the requisite majorities at Court ... of Tepnel shareholders voted in favor of the acquisition, which ... as a "scheme of arrangement" under English law. The ...
... Probiotic Works Naturally to Restore Oral HealthCHICAGO, March ... and Butler(R) brand products, has introduced GUM(R) PerioBalance(TM), ... for oral health. GUM(R) PerioBalance(TM) is available online ... GUM(R) PerioBalance(TM) e-store ( www.periobalance.com ) and at ...
... Health Segment Increases Annual RevenueLOVELAND, Colo., March 16 ... ("Heska" or the "Company") today reported financial results ... December 31, 2008, and year ended December 31, ... , "The poor economic environment had an impact ...
... led by Clifford Goodman, PhD, at the NCCN 14th Annual ... Cancer Care." The panel of experts tackled the spectrum of ... benefit to patients of some of the latest cancer treatments ... Oncology is an area of rapid growth, both in terms ...
Cached Medicine News:Health News:Important new model shows how proteins find the right DNA sequences 2Health News:Dendritic cells ensure immune tolerance 2Health News:Dendritic cells ensure immune tolerance 3Health News:Tepnel Shareholders Approve Acquisition by Gen-Probe 2Health News:Tepnel Shareholders Approve Acquisition by Gen-Probe 3Health News:Tepnel Shareholders Approve Acquisition by Gen-Probe 4Health News:New Probiotic Supplement Helps Consumers Fight Unhealthy Teeth and Gums 2Health News:New Probiotic Supplement Helps Consumers Fight Unhealthy Teeth and Gums 3Health News:Heska Announces Q4 and Annual 2008 Results 2Health News:Heska Announces Q4 and Annual 2008 Results 3Health News:Heska Announces Q4 and Annual 2008 Results 4Health News:Heska Announces Q4 and Annual 2008 Results 5Health News:Heska Announces Q4 and Annual 2008 Results 6Health News:Heska Announces Q4 and Annual 2008 Results 7Health News:Heska Announces Q4 and Annual 2008 Results 8Health News:Heska Announces Q4 and Annual 2008 Results 9Health News:Heska Announces Q4 and Annual 2008 Results 10Health News:Experts Weigh in on Controversial Issue of Determining Value of Cancer Care at NCCN Conference 2Health News:Experts Weigh in on Controversial Issue of Determining Value of Cancer Care at NCCN Conference 3Health News:Experts Weigh in on Controversial Issue of Determining Value of Cancer Care at NCCN Conference 4Health News:Experts Weigh in on Controversial Issue of Determining Value of Cancer Care at NCCN Conference 5
Attain Left-heart Lead Delivery Systems. Medtronic offers left-heart lead delivery systems to assist with accessing the coronary sinus (cs)....
... The Attain™ Deflectable Catheter - designed ... using a single catheter. Steerablility - Create ... procedure with a single, steerable guide catheter. ... desired shape to address each patient's unique ...
Attain LV Leads. Navigate minimally angled veins with little to moderate tortuosity....
... The Hancock® II bioprosthesis from ... years of proven clinical experience. ... the freedom from structural valve ... and mitral bioprostheses is substantially ...
Medicine Products: